Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry

Abstract

The present results confirm prior randomised controlled trial results in patients with type 2 diabetes from real world clinical practice demonstrating that DPP4-I on top of prior metformin monotherapy result in similar HbA1c reductions within 12 months but a significant reduction in hypoglycaemia compared with sulfonylurea added to metformin. The reduction in vascular events observed has to be verified in larger cohorts.

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

“…Effects on hospital admission for heart failure All five trials 9 evidence from observational studies Of 12 observational studies, four [109][110][111][112] reported heart failure, and eight 13-17 113-115 reported hospital admission for heart failure; nine 13-15 109-111 [113][114][115] were cohort studies and the other three 16 17 112 were nested case-control studies (fig 1). Observational studies reporting heart failure Of the four studies reporting heart failure, two prospective cohort studies 109 (table 4 and table 5).…”

“…Observational studies reporting heart failure Of the four studies reporting heart failure, two prospective cohort studies 109 (table 4 and table 5). Sample sizes ranged from 616 to 13 185, and the mean or median length of follow-up ranged from one to four years.…”

Effectiveness of Second-Line Agents in the Treatment of Uncomplicated Type 2 Diabetes Mellitus: An Observational Tertiary-Care Based Study

“…The upsurge in the trend towards DPP-4 inhibitor can be attributed to simple dosing regimen, oral administration, lesser adverse effects, better tolerability, insignificant hypoglycemic episodes, negligible weight alterations, and a desirable glycemic target achievement. 19 The pioglitazone usage was reported more between 2012-2014 in the study undertaken and contributed to 22.5% prescriptions among second-line agents. The usage of pre-mixed insulin (30% regular/70% NPH) was reported as 27.5% compared to a study conducted in Shimoga district of Karnataka (28.57%).…”

Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis—A review

“…Although their uses in diabetes are well established, there are contradictory perceptions regarding their impact on cardiovascular outcomes. In previous studies, it has been demonstrated that diabetic patients using DPP-4 inhibitors have lower risk of cardiovascular events compared to patients who were usingnon-DPP-4 medications [49][50][51]. Similarly, another study reflected that sitagliptin had a lower rate of cardiovascular events in comparison to sulphonylurea [52].…”